---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-076091"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2026-06-22T12:01:50+00:00"
generated_at: "2026-06-22T12:06:20.129943+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Definium Therapeutics reports positive Phase 3 results for DT120 ODT in major depressive disorder

## Summary
- Study met primary endpoint with 8.1-point MADRS placebo-adjusted improvement at Week 6 (p<0.0001)
- 7.3-point MADRS placebo-adjusted improvement at Week 12 (p<0.0001), showing durability
- DT120 ODT was generally well tolerated; no serious adverse events or suicidality signal
- Company to host webcast at 8:00 a.m. EDT on June 22, 2026 to discuss results

## SEC filing metadata
- accession: 0001104659-26-076091
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2026-06-22T12:01:50+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000110465926076091/0001104659-26-076091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000110465926076091/tm2618434d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-076091
- JSON: https://secwatch.observer/filing/0001104659-26-076091.json
- Plain text: https://secwatch.observer/filing/0001104659-26-076091.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.